SECUKINUMAB

Brand name:

• Cosentyx®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Non-radiographic axial spondyloarthritis; Severe active psoriatic arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Active ankylosing spondylitis; Severe chronic plaque psoriasis.

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New listing (–)

Comment:

--

Submission sponsor:

Novartis Pharmaceuticals Australia Pty Limited

Other PBAC consideration:

--

Submission received for:

March 2022 PBAC meeting

Opportunity for consumer comment:

Open 24/11/2021 and close 27/01/2022 (see PBS Website)

PBAC meeting:

Held on 09/03/2022

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

01/05/2025

Lodgement of required documentation:

13/05/2025

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 27/06/2025

Status:

Finalised

Government processes:

Commenced on 08/07/2025

Medicine listed on the PBS:

01/09/2025 (see PBS schedule)

---